hydrocodone/paracetamol / Generic mfg. - LARVOL DELTA

Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction (clinicaltrials.gov) - P2/3 | N=90 | Completed | Sponsor: Henry Ford Health System | N=62 ➔ 90

Enrollment change

Comparison of Multimodal Analgesia and Narcotic Regimen for Postoperative Pain Control of Plastic Surgery Breast Procedures. (PubMed, Eplasty) - "Patients received either multimodal analgesia (preoperative acetaminophen 1000 mg, postoperative tramadol 50 mg q6h PRN, and gabapentin 300 mg TID) or narcotic analgesia (hydrocodone-acetaminophen 5-325 mg q6h PRN). Multimodal analgesia provides pain control comparable to traditional narcotic regimens in breast procedures. This approach may reduce opioid exposure with comparable patient-reported outcomes, supporting multimodal analgesic protocols as a strategy to mitigate opioid use in plastic surgery patients."

Journal • Addiction (Opioid and Alcohol) • Pain

Randomized Controlled Trial Comparing a Multimodal Pain Protocol Versus Hydrocodone-Acetaminophen after Outpatient Orthopaedic Trauma Surgeries (AAOS 2026) - "Patients were randomized into two groups and given either a peripheral nerve block and a multimodal pain protocol (ibuprofen, acetaminophen, gabapentin, oxycodone) or a peripheral nerve block and hydrocodone-acetaminophen. The primary outcome of interest was morphine milligram equivalents (MMEs) consumed... There was no significant difference in MMEs consumed, pain scores or satisfaction with the implementation of a multimodal pain management protocol versus an opioid monotherapy regimen after outpatient orthopaedic trauma surgeries. Peripheral nerve blocks (PNBs) are likely the single most effective analgesic intervention, potentially diminishing the effect of opioid therapy and any differences in MMEs consumed between the study groups. The low to moderate pain scores consistently reported while MMEs consumed by both study groups remained low, suggests that post-operative analgesic regimens consisting of PNBs and limited opioid therapy may be sufficient for most..."

Clinical • Surgery • Orthopedics • Pain

Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Preliminary Analysis of a Prospective Randomized Controlled Trial (AAOS 2026) - "The study arms were an opioid sparing analgesic protocol (loading dose intravenous ketorolac, oral ketorolac, diazepam) and a standard opioid multimodal regimen (hydrocodone-acetaminophen and diazepam), and the primary outcome was postoperative visual analog scale (VAS) pain scores for 5 days and opioid medication usage recorded in pain journals. This study found similar postoperative pain control and significantly less opioid use with a ketorolac based opioid sparing pain protocol compared to the standard of care. Minimal adverse events were found in both cohorts and time from surgery was significantly associated with postoperative pain improvement."

Clinical • Addiction (Opioid and Alcohol) • Constipation • Gastroenterology • Gastrointestinal Disorder • Orthopedics • Pain

Synthetic Tetrahydrocannabinol (THC) is a Safe Adjunct to the Treatment of Postoperative Pain after Arthroscopic Knee Surgery: A Pilot Randomized Safety Trial (AAOS 2026) - "Exclusion criteria included patients under the age of 18, patients unable to provide consent, patients who are pregnant, breastfeeding, or trying to become pregnant, patients with an allergy to any of the study drugs, patients undergoing revision surgery or open surgery, patients with a history of mania, depression, or schizophrenia, patients currently diagnosed with alcohol or drug abuse, patients who cannot or will not abide by the medication regimen, or patients taking any of the following drugs: anticholinergic agents, benzodiazepines, central nervous system depressants, droperidol, hydroxyzine, levomepromazine, methotrimeprazine, monoamine oxidase inhibitors, ritonavir, selective serotonin reuptake inhibitors, sympathomimetics, St...Primary outcome for this pilot study was safety of the test drug with the secondary outcome being pain control and number of opioid tablets (hydrocodone-acetaminophen 5-325mg) consumed at 3 different time intervals: 24 hours, 48 hours,..."

Clinical • Surgery • Addiction (Opioid and Alcohol) • Bipolar Disorder • Depression • Immunology • Orthopedics • Pain • Schizophrenia • Xerostomia

USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS (ISPOR 2026) - "Among this cohort, drug utilization management was commonly applied and varied substantially across therapeutic areas and payors, suggesting a complex administrative and clinical landscape that is inconsistent for patients and providers alike."

Cardiovascular • Endocrine Disorders • Infectious Disease

Efficacy and Safety of LTG-001, a Selective NaV1.8 Inhibitor, in Patients with Moderate to Severe Pain after Abdominoplasty (AAN 2026) - "Participants were randomized 1:1:1:1 to oral LTG-001 high dose (450mg loading +300mg q12h; n=86), low dose (300mg loading +150mg q12h; n=85), hydrocodone/acetaminophen 5/325mg q6h (opioid reference; n=86), or placebo (n=86) for 48 h; oxycodone 5mg q6h was permitted as rescue... LTG-001 produced rapid, robust analgesia after abdominoplasty with favorable tolerability and significant opioid sparing. Placebo-adjusted 48-hour effect for high-dose LTG-001 (62.1) was the largest of any analgesic tested in abdominoplasty in a published industry-sponsored trial."

Clinical • Aesthetic Medicine • Pain • NAV1

Postoperative Pain Management in Rhinoplasty: A Double Blind Randomized Controlled Trial. (PubMed, Facial Plast Surg Aesthet Med) - "This trial demonstrates a lack of difference between opioid and non-opioid pain medications in postoperative pain control after rhinoplasty."

Clinical • Journal • Aesthetic Medicine • Pain

Suzetrigine for Acute Pain in the Emergency Department: A First-in-Class NaV1.8 Blocker. (PubMed, J Am Coll Emerg Physicians Open) - "In 3 phase 3 studies of patients with acute pain, mostly from surgical causes, suzetrigine produced clinically meaningful reductions in 48-hour pain scores vs placebo and analgesia equivalent to hydrocodone/acetaminophen...Studies of suzetrigine's use in the ED for nonsurgical pain must be conducted to ensure proper utilization. However, suzetrigine's oral formulation, preliminary favorable safety profile, and apparent lack of addictive potential based on early-stage trials align well with contemporary ED guidelines that prioritize multimodal, opioid-sparing analgesia, making it a promising addition to the armamentarium for pain management in the ED."

Clinical • Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Pain • Psychiatry • NAV1

Suzetrigine: A New Non-Opioid Analgesic Option With Potential Implications for Serious Illness Care. (PubMed, J Palliat Care) - "While clinical trials demonstrate its noninferiority to hydrocodone/acetaminophen in acute postsurgical settings, the authors highlight significant barriers to its use in palliative and hospice care. These limitations include a lack of evidence in patients with serious illness, a current safety restriction of 14 days of use, and a high cost of approximately $15.50 per tablet. Consequently, while suzetrigine represents a significant pharmacological advancement, its current utility is likely limited to short-term acute pain crises until further data support its long-term application in serious illness management."

Journal • Anesthesia • CNS Disorders • Depression • Oncology • Pain • Palliative care • Psychiatry • NAV1

Illicit Prescription Opioid Use Among U.S. Firefighters. (PubMed, Fire (Basel)) - "The most commonly misused opioids were hydrocodones with trade names Vicodin, Lortab, and Lorcet (72% of those illicitly using opioids)...Illicit prescription opioid use by firefighters is a potential problem especially when considered along with other factors such as mental health. Longitudinal studies are needed to further deepen our knowledge about this issue."

Journal • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Suzetrigine, a novel nonopioid analgesic for acute pain. (PubMed, Curr Opin Anaesthesiol) - "Suzetrigine shows significant potential to improve the treatment of moderate-to-severe acute pain of both surgical and nonsurgical origin."

Journal • Addiction (Opioid and Alcohol) • Pain • NAV1

Post-operative Pain Management in Children With Supracondylar Humerus Fractures (clinicaltrials.gov) - P4 | N=29 | Terminated | Sponsor: Baylor College of Medicine | N=100 ➔ 29 | Trial completion date: Jun 2025 ➔ Dec 2025 | Enrolling by invitation ➔ Terminated | Trial primary completion date: Dec 2024 ➔ Dec 2025; After reviewing our enrollment numbers and feasibility, we have decided to close the study due to low enrollment.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Musculoskeletal Diseases • Orthopedics • Pain

Opioid Prescribing Patterns of Board-Certified Emergency Physicians Compared With Other Physicians Practicing Emergency Medicine Among Medicare Part-D Beneficiaries Between 2018 and 2020 in the United States. (PubMed, J Am Coll Emerg Physicians Open) - "The average total day supply (TDS) of opioids per beneficiary for the 4 most common opioids (acetaminophen/codeine, hydrocodone/acetaminophen, oxycodone/acetaminophen, tramadol) was estimated using generalized linear models with Poisson distribution, log-link, and individual clustering and compared by board certification in EM status. Board certification in EM was associated with lower opioid prescribing rates. The average TDS of opioids per Medicare beneficiary was lower for board-certified EM physicians compared to non-EM board-certified physicians staffing EDs between 2018 and 2020."

Journal • Medicare • Reimbursement • US reimbursement • Pain

SCHF Post-Op Study Between Opioid and Non-Opioid Pain Management (clinicaltrials.gov) - P4 | N=160 | Active, not recruiting | Sponsor: Children's Mercy Hospital Kansas City | Enrolling by invitation ➔ Active, not recruiting | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Pain

Suzetrigine Was More Effective Than Placebo and Similar to Hydrocodone-Acetaminophen, 5 mg/325 mg for Postoperative Pain. (PubMed, Am Fam Physician) - No abstract available

Journal • Pain

Suzetrigine, a selective NaV1.8 inhibitor in acute and chronic pain: mechanistic insights, clinical outcomes, and future perspectives. (PubMed, Curr Opin Anaesthesiol) - "Suzetrigine represents a promising nonopioid alternative for acute pain and has the potential to fill a significant gap in pain management. While initial results are encouraging, future studies are needed to define its role in chronic pain and multimodal analgesia, and to establish long-term safety."

Clinical data • Journal • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain • NAV1

Abdominal wall blocks in robotic hysterectomy for endometrial cancer are associated with a modest reduction in the frequency of patients receiving post-operative intravenous opioids. (PubMed, Gynecol Oncol Rep) - "Fentanyl was excluded due to frequent intra-op use...Patients who received blocks were less likely to receive IV (52.5 % vs 64.8 %, RR 0.81, 95 % CI 0.73-0.89, p < 0.001) and oral hydromorphone (6.9 % vs 3.9 %, RR 2.53, 95 % CI 1.68-3.81, p < 0.001) and more likely to receive oral hydrocodone/acetaminophen (11.3 % vs 0.88 %, RR 12.77, 95 % CI 8.73-18.67, p < 0.001). Blocks are infrequently performed and are associated with a modest reduction in the number of patients receiving post-op IV opioids. We found no difference in LOS or cost. Limitations include lack of detail regarding type of block, anesthetic, and phase of care."

Journal • Anesthesia • Endometrial Cancer • Gynecology • Oncology • Solid Tumor

Clinical Efficacy and Safety Profile of Suzetrigine: A Novel Non-opioid Analgesic Targeting NaV1.8 Sodium Channel. (PubMed, Cureus) - "Suzetrigine exhibits high selectivity for the NaV1.8 channel through a novel allosteric mechanism with significant pain relief compared to placebo and comparable efficacy to a standard hydrocodone/acetaminophen combination. Its recent approval by the U.S. Food and Drug Administration for moderate to severe acute pain underscores its potential as an effective non-opioid therapeutic. While its short-term efficacy and safety are well established, future research should focus on its long-term safety profile and its utility across a broader range of pain conditions."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • NAV1

Postoperative Pain Management in Rhinoplasty (clinicaltrials.gov) - P2 | N=159 | Completed | Sponsor: Stanford University | Active, not recruiting ➔ Completed

Trial completion • Aesthetic Medicine • Pain

Treatment of Acute Postoperative Pain in Chronic Pain Patient Using Suzetrigine, a Novel Non-Opioid Analgesic (ASRA-FALL 2025) - "Trials have shown that it reduces moderate-to-severe acute pain comparably to hydrocodone/acetaminophen (Bertoch, 2025). We present a case of acute postoperative pain in a chronic pain patient with bilateral above-knee amputations (AKAs) who responded well to suzetrigine."

Clinical • Pain

A Rare Manifestation of Immune Checkpoint Inhibitor Toxicity (ACG 2025) - "Their use has significantly increased since ipilimumab was approved in 2011 for metastatic melanoma...We present a case of immune-mediated cholangitis (IMC) induced by ICI.Case Description/ An 80-year-old female with metastatic endometrial cancer presented to the emergency department with encephalopathy due to hydrocodone-acetaminophen taken for cancer-related pain. She took a 1-week course of trimethoprim-sulfamethoxazole (TMP-SMX) and completed pembrolizumab cycle 19 3 weeks prior to presentation...N-acetylcysteine and antibiotics were prescribed on admission...There are some data to suggest ursodiol may provide added benefit. Further research is necessary to provide diagnostic and management guidance. Figure: CT with contrast demonstrating bile duct thickeningFigure: ALP trend following initiation of glucocorticoids on Day 2"

Checkpoint inhibition • CNS Disorders • Endometrial Cancer • Gastrointestinal Disorder • Hepatology • Immunology • Melanoma • Oncology • Solid Tumor

Beyond Opioids: A Review of Suzetrigine for Acute Pain Management. (PubMed, Int J Mol Sci) - "However, suzetrigine appears less potent than hydrocodone-acetaminophen in this context, and it remains unclear how effective suzetrigine is in treating more severe postoperative pain. Notably, all current studies are limited to short durations of treatment; further studies will be required to delineate suzetrigine's long-term efficacy, safety, and addiction potential to be utilized in the management of chronic pain patients. This article provides a review of the current literature available on the use of suzetrigine in treating acute pain."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • NAV1

Efficacy of Methylprednisolone for Pain Control After ACL Repair (clinicaltrials.gov) - P4 | N=90 | Recruiting | Sponsor: St. Louis University | Enrolling by invitation ➔ Recruiting

Enrollment status • Pain

Effect of Regional Anesthesia on Discharge Opioids After Pediatric Sclerotherapy: A Follow Up Study (ASA 2025) - "309 patients were included in final analysis. 157 patients (50.8%) received opioids at discharge, primarily hydrocodone-acetaminophen (98.8%). Adjusted logistic regression revealed no association between nerve block use and being discharged with opioids (Odds ratio (OR) 0.98, 95% CI 0.45 to 2.14, p=1.00)."

Clinical • Anesthesia • Pediatrics